Apremilast in the Treatment of Uveitis

Stopped early · Phase 1/Phase 2

Conditions studied: Uveitis

In brief

The purpose of this study is to assess the safety and efficacy of Apremilast in the treatment of uveitis.

Key facts

Study ID

NCT00889421

Run by

Oregon Health and Science University

People needed

3

Starts

2009-11-01

Expected to finish

2011-06-01

Last updated by the study team

2014-07-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients with vision-threatening autoimmune uveitis
• failure to respond to prednisone and at least one other systemic immunosuppressive, or intolerance to such medications due to side effects

You may not qualify if…

• serious concomitant illness that could interfere with the subject's participation
• previous or current use of an alkylating agent
• use of CYP3A4 inhibitors during the trial
• TNF blocker use within the 8 weeks prior to enrollment

Where it is running

• Oregon Health & Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.